Sera Prognostics Achieves Remarkable Growth in Q3 2026 Financial Results

Sera Prognostics Reports Third Quarter 2026 Financial Results

Sera Prognostics, Inc., widely recognized as The Pregnancy Company, recently shared its financial results for the third quarter ending September 30, 2026. This report reveals a commanding growth in test volumes and provider engagement, marking a significant milestone in the company's journey toward enhancing maternal and neonatal health.

The financial report showcases that the PreTRM® test volumes surged by an impressive 54% sequentially, realizing nearly a five-fold increase since the first quarter of 2026. Furthermore, the number of ordering healthcare providers increased by 34% sequentially and tripled from the beginning of the year, underscoring a robust physician adoption of the PreTRM® test.

A notable development involves Florida becoming the second state to extend Medicaid coverage for the PreTRM® test, which has established pricing in the fee schedule. This legislative victory is pivotal as it positions the test as accessible to approximately 4 million Medicaid beneficiaries in Florida, translating to around 90,000 Medicaid births annually. The inclusion of this service within Medicaid will not only facilitate better maternal care but will also expand the market for Sera’s innovative testing service.

The quarterly revenue from the PreTRM® test reached $42,000, reflecting a year-over-year increase of 163%. Despite this growth, revenue was adversely affected by lower average selling prices due to an increased proportion of low or non-reimbursed tests. Operating expenses showed a decline of 11% sequentially, thanks to the cost-reduction strategies implemented earlier this year, although this was offset by increased spending in commercial initiatives associated with the launch efforts in Illinois and Florida.

Sera Prognostics is preparing for significant changes in the upcoming fiscal year as it expands its commercial organization to support the anticipated rise in test volume. These preparations come alongside the initiation of the CE Mark submission process for their kit-based PreTRM® Global test in Europe. This positioning reinforces the company’s commitment to establishing the PreTRM test as a foundational component of prenatal care, especially in light of positive references from the European Association for Perinatal Medicine guidelines.

The company is also progressing in its strategic initiatives, having adopted a collaborative approach with a national payer in a state-based payer partnership program aimed at enhancing PreTRM test-guided care implementation. Currently, discussions are underway with one of the largest commercial insurers regarding a large pilot project targeting multi-state, multi-thousand-patient enrollment, set to kick off in fiscal year 2027.

Moreover, the third quarter saw the expansion of Sera’s sales force by 25% to facilitate the commercialization process in Illinois and further bolster support for Florida’s rollout. These actions reflect the organization’s proactive approach toward increasing its presence across markets where reimbursement for the PreTRM test has been established.

The overarching narrative of the third quarter for Sera Prognostics is one of strategic growth and the robust validation of its business model. As they move forward, Sera is determined to enhance its clinical and health economic evidence base, paving the way for broader acceptance and application of their advanced diagnostic tools in prenatal care.

As the company concluded the quarter, cash and cash equivalents stood at $72.8 million, with an operating cash burn of $7.3 million during this period. With a firm footing and ambitious plans for upcoming quarters, Sera Prognostics aims to continue its impact on pregnancy health through innovative biomarker testing.

In conclusion, Sera Prognostics is at a significant juncture, transitioning from generating evidence to implementing commercially viable solutions. Their focus on establishing the PreTRM test as a critical diagnostic tool reflects a commitment not only to business growth but also to the essential mission of improving maternal and neonatal health across the United States.